These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35095082)

  • 1. Suitable Dose of Long-Term Tolvaptan to Reduce Heart Failure Rehospitalizations.
    Nishino M; Tanaka A; Kawanami S; Sugae H; Ukita K; Kawamura A; Nakamura H; Matsuhiro Y; Yasumoto K; Tsuda M; Okamoto N; Matsunaga-Lee Y; Yano M; Egami Y; Tanouchi J
    Int Heart J; 2022; 63(1):85-90. PubMed ID: 35095082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience with long-term administration of tolvaptan to patients with acute decompensated heart failure.
    Kiuchi S; Fujii T; Hisatake S; Kabuki T; Takashi O; Dobashi S; Ikeda T
    Drug Discov Ther; 2017 Jul; 11(3):133-139. PubMed ID: 28626112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease.
    Uemura Y; Shibata R; Takemoto K; Uchikawa T; Koyasu M; Ishikawa S; Mitsuda T; Miura A; Imai R; Iwamiya S; Ozaki Y; Kato T; Miura T; Watarai M; Murohara T
    Heart Vessels; 2016 Oct; 31(10):1643-9. PubMed ID: 26615607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of tolvaptan dose on cardiac mortality in patients with acute decompensated heart failure after hospital discharge.
    Matsumoto K; Ehara S; Nakamura Y; Otsuka K; Kawase Y
    Heart Vessels; 2018 Oct; 33(10):1204-1213. PubMed ID: 29687159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolvaptan Improves Prognosis in Responders with Acute Decompensated Heart Failure by Reducing the Dose of Loop Diuretics.
    Nakamura M; Sunagawa O; Kinugawa K
    Int Heart J; 2018; 59(1):87-93. PubMed ID: 29375117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Continuous Administration of Tolvaptan on Preventing Medium-Term Worsening Renal Function and Long-Term Adverse Events in Heart Failure Patients with Chronic Kidney Disease.
    Nakano Y; Mizuno T; Niwa T; Mukai K; Wakabayashi H; Watanabe A; Ando H; Takashima H; Murotani K; Waseda K; Amano T
    Int Heart J; 2018 Jan; 59(1):105-111. PubMed ID: 29332911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renoprotection by long-term low-dose tolvaptan in patients with heart failure and hyponatremia.
    Oka T; Hamano T; Ohtani T; Doi Y; Shimada K; Matsumoto A; Yamaguchi S; Hashimoto N; Senda M; Sakaguchi Y; Matsui I; Nakamoto K; Sera F; Hikoso S; Sakata Y; Isaka Y
    ESC Heart Fail; 2021 Dec; 8(6):4904-4914. PubMed ID: 34554640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypernatremia induced by low-dose Tolvaptan in a Patient with refractory heart failure: A case report.
    Li T; Li GS
    Medicine (Baltimore); 2019 Jul; 98(27):e16229. PubMed ID: 31277136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of renal function on mid-term outcomes in heart failure patients treated with tolvaptan.
    Fujioka K; Mizuno S; Ichise T; Matsui T; Hirase H; Yamaguchi M; Aoyama T; Yamagishi M; Fujino N; Kawashiri MA; Hayashi K
    Ther Adv Cardiovasc Dis; 2019; 13():1753944718819064. PubMed ID: 30803403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effect of long-term administration of tolvaptan in patients with heart failure and chronic kidney disease.
    Ono Y; Takamatsu H; Inoue M; Mabuchi Y; Ueda T; Suzuki T; Kurabayashi M
    Drug Discov Ther; 2018; 12(3):154-160. PubMed ID: 29998996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment　- Results From the K-STAR Study.
    Inomata T; Ikeda Y; Kida K; Shibagaki Y; Sato N; Kumagai Y; Shinagawa H; Ako J; Izumi T;
    Circ J; 2017 Dec; 82(1):159-167. PubMed ID: 28835586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodynamic and Hormonal Effects of Tolvaptan for Heart Failure.
    Kiuchi S; Ikeda T
    Intern Med; 2019 Feb; 58(4):471-475. PubMed ID: 30210135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of quality of life during long-term treatment of tolvaptan in refractory heart failure: design and rationale of the AQUA-TLV study.
    Imamura T; Kinugawa K; Ohtani T; Sakata Y; Higo T; Kinugawa S; Tsutsui H; Sunagawa K; Komuro I
    Int Heart J; 2014; 55(3):264-7. PubMed ID: 24806383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favorable effects of early tolvaptan administration in very elderly patients after repeat hospitalizations for acute decompensated heart failure.
    Kinoshita M; Okayama H; Kosaki T; Hosokawa S; Kawamura G; Shigematsu T; Takahashi T; Kawada Y; Hiasa G; Yamada T; Matsuoka H; Kazatani Y
    Heart Vessels; 2018 Feb; 33(2):163-169. PubMed ID: 28889231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights From the EVEREST Trial.
    Mecklai A; Subačius H; Konstam MA; Gheorghiade M; Butler J; Ambrosy AP; Katz SD
    JACC Heart Fail; 2016 Jul; 4(7):580-588. PubMed ID: 27039131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure.
    Imamura T; Kinugawa K; Fujino T; Inaba T; Maki H; Hatano M; Yao A; Komuro I
    Circ J; 2014; 78(9):2240-9. PubMed ID: 24954239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Long-Term Treatment With Tolvaptan to Prolong the Time Until Dialysis Initiation in Patients With Chronic Kidney Disease and Heart Failure.
    Tanaka A; Hiramatsu E; Watanabe Y; Ito C; Shinjo H; Otsuka Y; Takeda A
    Ther Apher Dial; 2019 Aug; 23(4):319-327. PubMed ID: 30569597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temporal Change in Renoprotective Effect of Tolvaptan on Patients with Heart Failure: AURORA Study.
    Nishino M; Egami Y; Tanaka A; Kawanami S; Sugae H; Ukita K; Kawamura A; Nakamura H; Matsuhiro Y; Yasumoto K; Tsuda M; Okamoto N; Matsunaga-Lee Y; Yano M; Tanouchi J
    J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure.
    Kimura K; Momose T; Hasegawa T; Morita T; Misawa T; Motoki H; Izawa A; Ikeda U
    J Cardiol; 2016 May; 67(5):399-405. PubMed ID: 26692119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of early use of tolvaptan in very elderly patients with acute decompensated heart failure.
    Niikura H; Iijima R; Anzai H; Kogame N; Fukui R; Takenaka H; Kobayashi N
    Anatol J Cardiol; 2017 Sep; 18(3):206-212. PubMed ID: 28777097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.